Drug Trial Radar · NCT01808768
Ocular Allergy Treatment Practical Impact Trial
Last checked: Nov 20, 2026Latest source record: May 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
Apr 2013
Primary completion
Oct 2013
Study completion Nov 2013
Sponsor
- Lead sponsor
- Starx Research Center, LLCIndustry
- Sponsor type
- Industry
- First posted
- Mar 11, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.
Conditions
- Allergic Conjunctivitis
- Rhinoconjunctivitis
Interventions
AlcaftadineDrug
Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Quality of Life- Eye Allergy Patient Impact QuestionnaireTime frame: 4 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
STARx Research Center
Edison, New Jersey · Recruiting
STARx
Springfield, New Jersey · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.